Admin
SRI International has announced that it has been awarded a $49 million, seven-year contract with NIH-subsidiary the National Institute of Allergy and Infectious Diseases, to conduct preclinical development of HIV infection and AIDS therapies.
The contract will support investigation into drug development and treatment of HIV and AIDS, as well as providing preventive techniques of sexually transmitted disease.
“SRI Biosciences has been supporting NIAID since 1991 in the development of new therapeutics for HIV/AIDS,” said Jon Mirsalis, Ph.D., D.A.B.T., managing director of SRI Biosciences and co-principal investigator for the program.
According to the World Health Organization, more than 35 million people are infected with HIV worldwide, despite major advances in treatment technology.
Through the contract SRI Biosciences scientists can provided preclinical services to help NIH staff develop, manufacture and analyze the data, and create the products needed to fulfill all regulatory requirements for Investigational New Drug (IND) applications.
“We look forward to making additional contributions to translating drug discoveries to the clinic,” said Helen Parish, executive director of the Pharmaceutical Development Section in SRI Biosciences.
The project is backed with Federal funds from the NIAID, the NIH and the Department of Health and Human Services.
